Novo Nordisk A/S : Share repurchase programme

Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 16 June 2014 - On 1 May 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK

15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014.
Since the announcement as of 10 June 2014, the following transactions have been made under the programme:

Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 6,006,000 1,408,427,363

10 June 2014 220,000 241.74 53,183,284

11 June 2014 260,000 244.82 63,653,356

12 June 2014 240,000 249.46 59,869,632

13 June 2014 260,000 247.88 64,449,164

Accumulated under the programme 6,986,000 1,649,582,799

With the transactions stated above, Novo Nordisk owns a total of 25,446,394 B shares of DKK 0.20, corresponding to 1.0% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 13 June 2014, Novo Nordisk has

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

[phone]

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 38 / 2014

Page 2 of 2

repurchased a total of 22,419,995 B shares equal to a transaction value of DKK
5,354,270,936.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately

40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's

B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information Media: Anne Margrethe Hauge	[phone]	[e-mail]
Investors: Kasper Roseeuw Poulsen	[phone]	[e-mail]
Jannick Lindegaard Denholt	[phone]	[e-mail]
Daniel Bohsen	[phone]	[e-mail]
Frank Daniel Mersebach (US)	[phone]	[e-mail]

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

[phone]

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 38 / 2014